Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study

Journal of Clinical Oncology

Volumn 18, Issue 22, 2000, Pages 3748-3757

  Bonneterre, J ^a   Thurlimann B ^a   Robertson, J F R ^a   Krzakowski, M ^a   Mauriac, L ^a   Koralewski, P ^a   Vergote, I ^a   Webster, A ^a   Steinberg, M ^a   Von Euler, M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PLACEBO; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; VAGINA BLEEDING;

EID: 0034669435     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.22.3748     Document Type: Article

References (28)

1. Top 5 cancers for females and males in the US
2. Cancer in the European community and its member states
3. Cancer statistics, 1993
4. Antiestrogens in the management of hormone-dependent cancer
5. Endocrine therapy of metastatic breast cancer
6. Endocrine therapy of advanced breast cancer
7. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years
8. Effects of tamoxifen on cardiovascular risk factors in women after 5 years of treatment
9. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: The Stockholm Breast Cancer Study Group
10. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer
11. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
12. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer. An overview of the randomised trials
13. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
14. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
15. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
16. Neoadjuvant treatment with anastrozole (Arimidex) causes profound suppression of intratumor estrogen levels
17. Aromatase inhibitors in advanced breast cancer: Mechanism of action and clinical implications
18. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
19. Assessment of response to therapy in advanced breast cancer
20. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
21. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy
22. Clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer
23. Static disease on anastrozole provides similar benefits as objective response in patients with advanced breast cancer
24. Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer
25. First-line fadrozole HCL (GCS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer: Prospective randomized trial of the Swiss Group for Clinical Cancer Res SAKK 20/88
26. Tamoxifen flare in advanced breast cancer
27. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: A possible model for tamoxifen tumour flare
28. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma